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Candida species are common causes of bloodstream infections (BSI), with highmortality. Four species cause>90% of Candida
BSI: C. albicans, C. glabrata, C. parapsilosis, and C. tropicalis. Differentiation of Candida spp. is important because of differ-
ences in virulence and antimicrobial susceptibility. CandidaQuickFISH BC, a multicolor, qualitative nucleic acid hybridization
assay for the identification of C. albicans (green fluorescence), C. glabrata (red fluorescence), and C. parapsilosis (yellow fluo-
rescence), was tested on Bactec and BacT/Alert blood culture bottles which signaled positive on automated blood culture devices
and were positive for yeast by Gram stain at seven study sites. The results were compared to conventional identification. A total
of 419 yeast-positive blood culture bottles were studied, consisting of 258 clinical samples (89 C. glabrata, 79 C. albicans, 23 C.
parapsilosis, 18 C. tropicalis, and 49 other species) and 161 contrived samples inoculated with clinical isolates (40 C. glabrata, 46
C. albicans, 36 C. parapsilosis, 19 C. tropicalis, and 20 other species). A total of 415 samples contained a single fungal species,
with C. glabrata (n 129; 30.8%) being the most common isolate, followed by C. albicans (n 125; 29.8%), C. parapsilosis (n
59; 14.1%), C. tropicalis (n 37; 8.8%), and C. krusei (n 17; 4.1%). The overall agreement (with range for the three major
Candida species) between the twomethods was 99.3% (98.3 to 100%), with a sensitivity of 99.7% (98.3 to 100%) and a specificity
of 98.0% (99.4 to 100%). This study showed that CandidaQuickFISH BC is a rapid and accurate method for identifying C. albi-
cans, C. glabrata, and C. parapsilosis, the three most common Candida species causing BSI, directly from blood culture bottles.
Candida species are ranked as the third or fourthmost commonetiologic agents associated with nosocomial bloodstream in-
fections (1, 2). Mortality rates are estimated to be as high as 45%
(3, 4), due in part to slowdiagnosticmethods and to inappropriate
initial antifungal treatment (5, 6). Candida albicans and other
yeasts reside as commensals of the skin andmucousmembranes of
the gastrointestinal and genitourinary tracts, causing infection
when the host becomes debilitated or immunocompromised. Risk
factors for invasive candidiasis include central venous catheters,
parenteral nutrition, organ transplantation, hemodialysis, sur-
gery, burns, long-term stay in an intensive care unit, and previous
administration of broad spectrum antimicrobial and immuno-
suppressive agents (7, 8).
The most commonCandida species found in healthy individu-
als includeC. albicans,C. glabrata,C. tropicalis, andC. parapsilosis
(9). These species causemore than 90%of invasive infections (10).
However, the prevalence of these different Candida species varies
widely geographically, and their antifungal susceptibilities are spe-
cies specific (11). Consequently, rapid, accurate identification of
the causative Candida species is critical for successful treatment.
Currently, blood culture is the gold standard method for the
diagnosis of fungal bloodstream infection (12). When growth is
detected, blood culturemedium is drawn for Gram stain and sub-
culture on agar plates for subsequent phenotypic identification
(13), which typically takes at least 72 h (14). To overcome this
relatively long turnaround time of identification, several molecu-
lar methods have been evaluated for identification of yeasts di-
rectly from blood culture bottles such as real-time PCR, matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF)
mass spectrometry, and peptide nucleic acid fluorescence in situ
hybridization (PNA-FISH) (15, 16). A method to detect Candida
directly from patient’s blood specimens within 3 h has also been
developed (17, 18).
The first generation of yeast PNA-FISH (AdvanDx, Woburn,
MA) distinguishes between the five commonest Candida species
directly from positive blood cultures within 90 min. The method
uses fluorescence-labeled probes to complement species-specific
rRNA sequences:C. albicans andC. parapsilosis fluoresce green,C.
tropicalis fluoresces yellow, and C. glabrata and C. krusei fluoresce
red. The assay cannot distinguish between C. albicans and C.
parapsilosis or between C. glabrata and C. krusei (15). A second-
generation yeast PNA-FISH, PNA Candida QuickFISH BC
(AdvanDx), is faster (30 min) and able to differentiate between
the most common Candida spp.: C. albicans fluoresces green, C.
glabrata fluoresces red, andC. parapsilosis fluoresces yellow, while
other yeasts do not produce any fluorescence.
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TheC. albicans probe is species specific and does not react with
C. dubliniensis. Similarly, the C. parapsilosis probe does not react
with C. orthopsilosis or C. metapsilosis. However, the C. glabrata
probe does react with C. bracarensis and C. nivariensis (16).
In the present study, we used a prototype lot of PNA Candida
QuickFISH BC (AdvanDx). Candida QuickFISH BC is a FISH
method using peptide nucleic acid (PNA) probes designed to de-
tect specific rRNA sequences of yeast species onmicroscope slides
from positive blood culture bottles. Fluorophore-labeled PNA
probes that target unique rRNA sequences and quencher probes
that target unbound PNA probes are added to smears and hybrid-
ized at 55°C for 15 min. PNA probes that do not bind to target
rRNA sequences will bind to a quencher probe to form a nonfluo-
rescent probe-quencher complex. Routinely, bloodstream infec-
tions caused by yeast are presumptively identified by Gram stain
from positive blood cultures, with final identification and differ-
entiation requiring subculture and biochemical analysis, which
can take several days.We usedCandidaQuickFISH BC to identify
Candida species directly from positive blood culture bottles in a
multicenter study at seven institutions.
MATERIALS AND METHODS
Samples from clinical and contrived blood culture bottles were tested at
seven study sites with a prototype lot of Candida QuickFISH BC. Clinical
samples were obtained from routine blood cultures at all seven study sites.
Testing was performed on bottles that signaled positive on automated
blood culture devices and showed yeast by Gram stain within 48 h of
bottles signaling positive. Contrived samples were produced at five study
sites using simulated blood cultures, with aliquots of blood brothmedium
(using 10 ml of blood per bottle) inoculated with fresh subcultures of
clinical isolates. These were incubated with shaking at 35 to 37°C until
yeast were visible upon Gram stain, which in most cases was within 24 h.
CandidaQuickFISH BCwas performed according to themanufactur-
er’s directions. Briefly, 10 l of fluid from a positive blood culture bottle
and one drop of QuickFix-1 were mixed on the sample area of the Quick-
FISH slide, left to dry (1 to 3 min), and then 2 drops of QuickFix-2 were
added and allowed to dry for 1 min. One drop each of Candida PNA blue
and Candida PNA yellow were mixed on a coverslip, which was placed
onto the QuickFISH slide that contained the fixed blood sample, followed
by incubation for 15min at 55°C using the supplied heat block. The slides
were then examined by fluorescencemicroscopy using appropriate filters.
Green fluorescence indicates C. albicans, red fluorescence indicates C.
glabrata, and yellow fluorescence indicates C. parapsilosis, whereas no
fluorescence indicates a yeast other than C. albicans, C. glabrata, or C.
parapsilosis.
The QuickFISH BC results were compared to conventional identifica-
tion (germ tube test, growth or morphology on fungal media, and iden-
tification by API 20C, Phoenix, or Vitek yeast biochemical card, as appro-
priate). Since conventional identification systems may not distinguish C.
parapsilosis fromC. orthopsilosis andC. metapsilosis, samples identified by
conventional identification asC. parapsilosiswere submitted for sequence
analysis to distinguish between these species.
RESULTS
A total of 419 yeast-positive blood culture bottles were studied at
the seven study sites, consisting of 258 clinical samples and 161
seeded samples (Table 1). Blood culture bottle types included
BacT/Alert aerobic and anaerobic bottles and Bactec aerobic, an-
aerobic, and pediatric bottles (Table 2). The distribution of yeast
species in the clinical and contrived samples is shown in Table 3.
Sixty-five samples initially identified by conventional testing as C.
parapsilosis were sequenced, and the results were as follows: 59 C.
parapsilosis, 3 C. metapsilosis, 2 C. orthopsilosis, and 1 C. tropicalis
sample.
A total of 415 samples contained a single fungal species, withC.
glabrata (n  129; 30.8%) being the most common isolate, fol-
lowed by C. albicans (n  125; 29.8%), C. parapsilosis (n  59;
14.1%),C. tropicalis (n 37; 8.8%), andC. krusei (n 17; 4.1%).
Four clinical samples contained two fungal species:C. albicans and
C. glabrata (n  2), C. glabrata and C. tropicalis (n  1), or C.
albicans and C. parapsilosis (n 1). Of the 258 clinical specimens
studied, it was noted that 217 were in aerobic and 41 in anaerobic
bottles. It was further noted that the species distribution between
aerobic and anaerobic bottle types differed, with 39.3% of the 89
C. glabrata versus 3.6%of the 169 other yeast species present in the
anaerobic bottles (P  0.0001). C. glabrata was found in 85.4%
(35/41) of the clinical anaerobic bottles.
The overall agreement between conventional identification
and QuickFISH BC was 99.3% (416/419) (Table 4). Agreement
was 100% for C. albicans (n  125), C. glabrata (n  129) and
mixed Candida species (n  4). Agreement was 98.3% for C.
parapsilosis (58/59), with no fluorescence detected in the one dis-
crepant sample. There was 98.0% agreement (100/102) for other
yeast species, with yellow fluorescence in the two discrepant sam-
ples, one ofwhich containedC.metapsilosis and the other of which
contained C. tropicalis. The overall sensitivity was 99.7%, and the
specificity was 98.0%.
TABLE 1 Numbers of clinical and contrived samples tested from each
study site
Study site
No. of samples
Clinical Contrived
Case Western Reserve University 32 NAa
Cedars Sinai Medical Center 21 41
Columbia University Medical Center 37 39
Detroit Medical Center 25 NA
Indiana University 65 38
Johns Hopkins Hospital 47 3
University of Virginia 31 40
Total 258 161
a NA, not applicable.
TABLE 2 Distribution of clinical and contrived blood culture bottle
types studied
Blood culture system
and bottle typea
No. of bottles studied
Clinical Contrived Total
BacT/Alert
Aerobic 53 38 91
Anaerobic 10 2 12
Bactec
Aerobic 154 104 258
Anaerobic 31b 17 48
Pediatric 10 0 10
Total 258 161 419
a All bottles were standard bottles unless indicated otherwise.
b Four of these bottles were Bactec Anaerobic Plus bottles.
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DISCUSSION
Currently, blood culture is the gold standardmethod for diagnosis
of fungal bloodstream infections (12). When growth is detected,
blood culture medium is sampled for Gram stain and subculture
on agar plates for subsequent phenotypic identification (13),
which typically takes at least 72 h (14). To overcome this relatively
long turnaround time of identification, several molecular meth-
ods have been evaluated for identification of Candida species di-
rectly from blood culture bottles, such as real-time PCR (19, 20),
multiplex-tandem PCR (21), PCR–high-resolution derivative
melt analysis (22), PCR-electrospray ionization mass spectrome-
try (23), DNA microarray (24), and PCR FilmArray (25). Other
new detection technologies include CHROMagar (26), random
amplified polymorphic DNA (27), MALDI-TOF mass spectros-
copy (28–30), and PNA-FISH (15, 16, 31, 32). Recently, a new
method to detect Candida directly from blood samples without
culture has been developed, with a limit of detection of 1 CFU/ml
of blood and a turnaround time of under 3 h (17, 18).
In our multicenter evaluation of a prototype lot, the Candida
QuickFISH BC method for rapid identification directly from
blood culture bottles of the three most common Candida species
(C. albicans, C. glabrata, and C. parapsilosis) was found to be sen-
sitive, specific, and rapid. Furthermore, these three species were
indeed shown to be the three most common yeast species present
in clinical samples, being present in 74.0% of these samples. Indi-
vidually, C. glabrata accounted for 34.5%, C. albicans accounted
for 30.6%, and C. parapsilosis accounted for 8.9% of the clinical
isolates. An interesting observation was that C. glabrata was the
yeast species present in 85.4% (35/41) of the clinical anaerobic
bottles studied, a finding in agreement with a recent publication
documenting exclusive or earlier growth of C. glabrata in anaero-
bic vials in a large series of candidemic patients from two Euro-
pean hospitals (33).
The Candida QuickFISH BC procedure is simple, and results
are obtained in about 30 min. All C. glabrata (129/129) and C.
albicans (125/125) isolates and all but one of the 59 C. parapsilosis
isolates were correctly identified compared to conventionalmeth-
ods.C. parapsilosis has recently been reclassified into three species:
Candida parapsilosis (sensu stricto), Candida orthopsilosis, and
Candida metapsilosis (34). Several in vitro studies have demon-
strated differences in the geographical distribution, expression of
virulence factors, and susceptibility to antifungal agents of these
Candida spp. (35, 36). Differentiation within the C. parapsilosis
complex is based on a variety of DNA techniques, such as internal
transcriber spacer sequencing (37, 38).
Of the 102 yeast species other thanC. albicans,C. glabrata, and
C. parapsilosis, the results of Candida QuickFISH BC were nega-
tive, in agreement with conventional methods, except for two
samples, with the two discrepant results associated with false-pos-
itive yellow fluorescence for 1 of 5 samples containing C. metap-
silosis and 1 of 37 samples containing C. tropicalis. The overall
agreement between Candida QuickFISH BC and conventional
methods was 99.3% (416/419). The C. albicans probe was species
TABLE 3 Identification of the yeast species present in the 419 samples
studieda
Yeast speciesa
No. of samples
Clinical Contrived Total (%)
Candida glabrata 89 40 129 (30.8)
Candida albicans 79 46 125 (29.8)
Candida parapsilosis 23 36 59 (14.1)
Candida tropicalis 18 19 37 (8.8)
Candida krusei 12 5 17 (4.1)
Candida guilliermondii 7 1 8 (1.9)
Candida lusitaniae 3 4 7 (1.7)
Candida dubliniensis 3 3 6 (1.4)
Candida metapsilosis 2 3 5 (1.2)
Candida orthopsilosis 3 1 4 (1.0)
Candida kefyr 2 1 3 (0.7)
Candida auris 1 1 (0.2)
Candida famata 1 1 (0.2)
Candida rugosa 1 1 (0.2)
Candida zeylanoides 1 1 (0.2)
Candida species, mixeda 4 4 (1.0)
Cryptococcus neoformans 6 6 (1.5)
Exophilia dermatitidis 1 1 (0.2)
Malassezia pachydermatis 1 1 (0.2)
Rhodotorula spp. 1 1 (0.2)
Saccharomyces cerevisiae 1 1 2 (0.5)
Total 258 161 419 (100)
a For the Candida species used in the study, the numbers of clinical and contrived
samples and the percentage of each Candida species are shown.
b That is, C. albicans/C. glabrata (n 2), C. glabrata/C. tropicalis(n 1), and C.
albicans/C. parapsilosis (n 1).
TABLE 4 Comparison between Candida QuickFISH BC and conventional identification
Parameter C. albicans C. glabrata C. parapsilosis Other Mixeda Total
Conventional Candida QuickFISH BC
identification (no. of strains)
C. albicans (green) 125 0 0 0 0 125
C. glabrata (red) 0 129 0 0 0 129
C. parapsilosis (yellow) 0 0 58 2b 0 60
Mixed fluorescence 0 0 0 0 4 4
No fluorescence 0 0 1 100 0 101
Agreement, sensitivity, or specificity (%)
Agreement 100 (125/125) 100 129/129 98.3 (58/59) 98.0 (100/102) 100 (4/4) 99.3 (416/419)
Sensitivity 100 (125/125) 100 (129/129) 98.3 (58/59) NAc NA 99.7 (312/313)
Specificity 100 (290/290) 100 (286/286) 99.4 (354/356) 99.5 (417/419) NA 98.0 (100/102)
a That is, C. albicans/C. parapsilosis (n 1), C. albicans/C. glabrata (n 2), and C. glabrata/C. tropicalis (n 1).
b Candida metapsilosis (n 1) and Candida tropicalis (n 1).
c NA, not applicable.
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specific and did not react with any of the other yeast species tested,
including 6 C. dubliniensis isolates. The C. parapsilosis probe did
show two false-positive reactions, one withC. metapsilosis and the
other withC. tropicalis, but did not react with 4C. orthopsilosis, 17
other C. tropicalis, or 4 other C. metapsilosis isolates. The C.
glabrata probe was species specific, althoughmolecular character-
ization was not performed to distinguish this species from C. bra-
carensis or C. nivariensis.
There are many implications of rapid identification of C. albi-
cans, C. glabrata, and C. parapsilosis on therapy and antimicrobial
stewardship. Technologies enabling rapid diagnosis of invasive
candidiasis and the determination of the species of Candida iso-
lates, such as T2 Candida, PNA-FISH, and MALDI-TOFMS, will
allow appropriate, cost-effective treatment of patients with candi-
diasis. This rapid identification of yeast species will limit unnec-
essary use of antifungal agents and enable antifungal stewardship
programs to improve care of patients with systemic candidiasis
(39). Antifungal therapy ofCandida bloodstream infections is fre-
quently inappropriate and delayed, resulting in increased hospital
stay and costs (40, 41).
Current clinical practice guidelines of the Infectious Disease
Society of America for the management of candidiasis recom-
mend that several factors be considered to guide therapy. These
include any history of recent azole exposure and intolerance to
antifungal agents, predominant localCandida species and suscep-
tibility data, disease severity, the presence of comorbidities, and
central nervous system, cardiac valve, or visceral organ involve-
ment (42). These guidelines note that successful treatment de-
pends on early initiation of effective antifungal therapy, with
higher mortality rates occurring when therapy is delayed. Flu-
conazole is recommended as a first-line therapy for patients with
mild to moderate illness, who have had no previous azole expo-
sure, and who do not have a high risk of C. glabrata infection.
Amphotericin B should be used for endocardial or central nervous
system infection or an echinocandin for endocardial candidiasis,
followed by fluconazole for patients with susceptible isolates who
improved clinically after initial therapy. Echinocandins are rec-
ommended for patients withmoderately severe to severe illness or
recent azole exposure, whereas fluconazole is suggested for pa-
tients who are not critically ill and have had no recent azole expo-
sure. Echinocandins can be changed to fluconazole for clinically
stable patients with C. albicans infection. Echinocandins are pre-
ferred for infections due to C. glabrata, whereas fluconazole is
recommended for infections due to C. parapsilosis. For C. krusei
infections, a short course of intravenous echinocandin therapy,
followed by oral fluconazole or voriconazole, is suggested.
Limitations of the Candida QuickFISH BC assay include the
detection of only three yeast species (although this encompasses
the most commonly encountered Candida species), the relatively
high cost of the assay, and the need for well-trained personnel to
read the assay using fluorescence microscopy. Another limitation
of the study is that a prototype lot of the Candida QuickFISH BC
assay was used, pending results of stability and functionality of
large-scalemanufacturing lots, whichmay requiremodification of
noncoding parts of the probes. Other platforms for the rapid de-
tection of yeasts, such as PCR, are also limited by high cost and a
low number of targets, with several assays targeting only a small
number of species (C. albicans, C. glabrata, C. krusei, C. parapsi-
losis, and C. tropicalis) due to limitations of the multiplexing ca-
pacities of many real-time PCR systems (43–45).
In conclusion, this multicenter study demonstrated the high
sensitivity of the Candida QuickFISH BC assay in detecting the
threemost commonCandida species associated with bloodstream
infections, C. albicans, C. glabrata and C. parapsilosis, and high
specificity in differentiating these three Candida species from
other yeast species.
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